Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
- Conditions
- TuberculosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 600
- Registration Number
- NCT00000959
- Locations
- 🇺🇸
Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States
🇺🇸Clinical Directors Network of Region II, New York, New York, United States
🇺🇸Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-11
- Target Recruit Count
- 44
- Registration Number
- NCT00004736
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-08
- Target Recruit Count
- 44
- Registration Number
- NCT00000778
- Locations
- 🇺🇸
Tulane Univ Med School, New Orleans, Louisiana, United States
🇺🇸UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Harbor - UCLA Med Ctr, Torrance, California, United States
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
- Conditions
- TuberculosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 50
- Registration Number
- NCT00000950
- Locations
- 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸Beth Israel Med Ctr, New York, New York, United States
🇺🇸Queens Med Ctr, Honolulu, Hawaii, United States
Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
- Conditions
- TuberculosisHIV Infections
- First Posted Date
- 2001-07-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00018083
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users
- Conditions
- Tuberculosis
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 300
- Registration Number
- NCT00004740
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.